Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Not recruitingRare disease

Evaluation of Dazodalibep Efficacy and Safety in Patients with Moderate-to-Severe Sjögren’s Syndrome: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study

Fast replyInvestigationalNo placebo
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Featured sites

Sites that work closely with us on this trial

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying Sjögren’s Syndrome, a condition that affects the body's moisture-producing glands, leading to symptoms like dry mouth and eyes. The study will evaluate a treatment called Dazodalibep, also known by its code name HZN-4920. This treatment is given as a solution for infusion, which means it is administered directly into the bloodstream through a vein.

The purpose of the study is to assess how well Dazodalibep works in reducing the symptoms of Sjögren’s Syndrome in people who experience moderate to severe symptoms. Participants in the study will receive either the treatment or a placebo, which is a substance with no active medication. The study will last for several weeks, during which participants will have regular check-ups to monitor their symptoms and overall health.

Throughout the study, participants will be asked to report on their symptoms and any changes they experience. The goal is to determine if Dazodalibep can provide relief from the symptoms of Sjögren’s Syndrome and to ensure that it is safe for use. The study will help researchers understand the potential benefits and any side effects of the treatment.

The research process

The trial runs in 2 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Study participation and medication administration

    You will receive either the test medication, called dazodalibep, or a placebo, which is a substance that contains no active medicine. this is done through an intravenous infusion, meaning the liquid is delivered directly into a vein.

    The dazodalibep is provided as a solution for infusion at a dose of 9999 mg.

  2. Step 2

    Monitoring and evaluation

    The effects of the medication on sjögren’s syndrome symptoms, such as dryness, pain, and fatigue, are monitored throughout the study.

    Assessments of your symptoms and salivary flow, which is the amount of saliva produced, are conducted to track changes over time.

    The study includes evaluations at week 12, week 24, and week 48 to measure how much your symptoms change compared to the start of the trial.

Who can join the trial?

14 criteria

  • You must be an adult, meaning at least 18 years old at the time you agree to join the study.
  • You must have a confirmed diagnosis of Sjögren’s syndrome, an autoimmune condition where the body attacks its own moisture-producing glands.
  • Your diagnosis must be confirmed by specific medical criteria, which may include testing for anti-Ro autoantibodies (proteins in your blood that indicate an immune system issue) or rheumatoid factor (a protein often found in people with autoimmune diseases).
  • You must have a score of 5 or higher on the ESSPRI, which is a tool used to measure how much symptoms like dry eyes or dry mouth affect your daily life.
  • You must have a score of less than 5 on the ESSDAI, which is a tool used to measure how much the disease is affecting your body's organs and systems.
  • You must still have some level of salivary gland function, meaning your mouth is still able to produce a certain amount of saliva when stimulated.
  • You must be able to complete patient-reported outcomes, which are forms where you describe your own symptoms and health status, without needing help from others.
  • You must be able to provide informed consent, which means you understand the study details and agree to participate in writing.
  • Women who are able to become pregnant must use highly effective contraception (methods to prevent pregnancy, such as birth control pills, an IUD, or other reliable methods) and must have regular pregnancy tests to confirm they are not pregnant.
  • You must not have active tuberculosis (TB), a serious bacterial infection that usually affects the lungs.
  • You must not have latent tuberculosis (a sleeping form of the infection) unless you have already finished the required medical treatment for it.
  • You must have had no recent close contact with anyone who has active tuberculosis.
  • You must have a negative Interferon Gamma Release Assay (IGRA), which is a specific blood test used to check if you have been infected with tuberculosis.
  • You must have a clear chest radiograph (an X-ray of your chest) that shows no signs of current tuberculosis or other significant lung issues.

Who cannot join the trial?

17 criteria

  • People who have had a blood clot in a deep vein (deep venous thrombosis), a blockage in the lung (pulmonary embolism), or a blockage in an artery (arterial thromboembolism) within the last 2 years.
  • People with a history of or currently having polymyositis, dermatomyositis (muscle and skin inflammation diseases), or systemic sclerosis (a condition that causes hardening of the skin and tissues).
  • People with active cancer or a history of cancer within the last 5 years, except for certain types of skin or cervical cancer that were successfully treated.
  • People who are pregnant, breastfeeding, planning to become pregnant, or planning to donate eggs during the study or for 3 months after the last dose.
  • People who test positive for Hepatitis B, Hepatitis C, or HIV (a virus that affects the immune system). This includes people with advanced scarring of the liver (cirrhosis) caused by Hepatitis C.
  • People who test positive for SARS-CoV-2 (the virus that causes COVID-19) on the day they are chosen to start the study.
  • People who have had certain infections in the last 12 months, such as opportunistic infections (infections that happen more easily in people with weakened immune systems), or people currently fighting an infection that requires systemic treatment (medicine that travels through the whole body).
  • People with a known severe allergy to any part of the study medication or to other biologic therapies (medicines made from living organisms).
  • People with severe or life-threatening issues regarding the heart (cardiovascular), lungs (respiratory), hormones (endocrine), digestion (gastrointestinal), blood (hematological), nerves (neurological), mental health (psychiatric), or other major body systems.
  • People who, in the doctor's opinion, cannot or will not follow the study rules, including those struggling with drug or alcohol abuse.
  • People who have received a live vaccine (a vaccine containing a weakened form of the germ) in the 4 weeks before the study or plan to get one during the study.
  • People who have used other experimental drugs or biologic agents (specialized medicines) within 6 months before the study or within specific timeframes for B-cell-targeting therapies (medicines that affect specific immune cells).
  • People who have used systemic corticosteroids (strong anti-inflammatory medicines that affect the whole body) for reasons other than specific autoimmune diseases for more than 2 weeks in the last 6 months.
  • People who have recently started or changed the dose of certain medications, including antimalarials, immunosuppressants (medicines that lower the immune system), or nonsteroidal anti-inflammatory drugs (common pain relievers).
  • People using certain eye drops to treat inflammation or herbal/homeopathic remedies for joint and muscle conditions within a few weeks of starting the study.
  • People who have ever used anti-CD40L compounds (a specific type of medicine used to affect the immune system).
  • People whose blood tests show abnormal levels of liver enzymes (AST and ALT), bilirubin (a substance related to liver function), hemoglobin (a protein in red blood cells), neutrophils or lymphocytes (types of white blood cells), platelets (cells that help blood clot), or INR (a measure of how long it takes blood to clot).
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

Dazodalibep is an experimental medication being tested to see if it can help improve the symptoms experienced by people with Sjögren’s syndrome.

What is already known about the treatment

  • Dazodalibep

    This medication is provided as a liquid solution that is administered directly into a vein through an infusion. It is currently being studied in advanced clinical trials to see how well it works for people with moderate-to-severe symptoms of Sjögren’s syndrome. As an experimental immune system modulator, it works at a molecular level to help regulate the body's immune response to reduce inflammation and symptoms. This drug belongs to a class of medications designed to target specific parts of the immune system to manage autoimmune conditions.

  • Placebo

    This is an inactive substance formulated as a sterile liquid intended to be mixed with a salt solution and given through a vein. It contains no active medicinal ingredients and is used in clinical studies as a control to compare against the actual test drug. The purpose of this substance is to help researchers determine if the effects seen in patients are truly caused by the medication being tested. It is classified as an inactive control substance used for scientific comparison.

Investigated diseases

Sjögren’s syndrome - This is a chronic condition where the body's immune system mistakenly attacks its own healthy cells, specifically targeting the glands that produce moisture. It often results in a significant reduction in saliva and tear production. As the condition progresses, individuals may experience persistent dryness in the mouth and eyes. This can lead to discomfort, fatigue, and various aches or pains throughout the body. The severity of these symptoms can fluctuate over time.
Trial detailsLast updated 2 Oct 2026
Age18+ yearsPhasePhase IIITrial ID2023-503923-24-00Protocol codeHZNP-DAZ-303Estimated enrolment457 patientsSponsorHorizon Therapeutics Ireland Designated Activity Company

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

ClinicalTrials.eu

Every clinical trial in Europe, in plain language.

Explore the full ecosystem of clinical research in Europe.

Search trials

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).